Patent classifications
C07D251/52
IDH1 INHIBITORS FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES AND SOLID TUMORS
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
CFTR REGULATORS AND METHODS OF USE THEREOF
Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.
CFTR REGULATORS AND METHODS OF USE THEREOF
Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.
COMPOSITION, FILM, LENS, SOLID STATE IMAGING ELEMENT, AND COMPOUNDS
An object of the present invention is to provide a composition capable of forming a film having a high refractive index and excellent exterior characteristics. Another object of the present invention is to provide a film, a lens, and a solid-state imaging element in which the composition is used. Still another object of the present invention is to provide novel compounds.
The composition according to an embodiment of the present invention contains a compound represented by General Formula (I), a solvent, and a resin, in which a solubility of the compound represented by General Formula (I) in the solvent is less than 0.5% by mass at 25 C., and a maximum absorption wavelength of the compound represented by General Formula (I) at a wavelength range of 300 to 800 nm is equal to or shorter than 450 nm.
AB-C).sub.n (I)
COMPOSITION, FILM, LENS, SOLID STATE IMAGING ELEMENT, AND COMPOUNDS
An object of the present invention is to provide a composition capable of forming a film having a high refractive index and excellent exterior characteristics. Another object of the present invention is to provide a film, a lens, and a solid-state imaging element in which the composition is used. Still another object of the present invention is to provide novel compounds.
The composition according to an embodiment of the present invention contains a compound represented by General Formula (I), a solvent, and a resin, in which a solubility of the compound represented by General Formula (I) in the solvent is less than 0.5% by mass at 25 C., and a maximum absorption wavelength of the compound represented by General Formula (I) at a wavelength range of 300 to 800 nm is equal to or shorter than 450 nm.
AB-C).sub.n (I)
Small molecules for inhibiting male fertility
Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic the binding of anti-EPPIN antibodies to EPPIN, and thus inhibit the forward motility of sperm in humans and other primates. In another embodiment, the compounds described herein inhibit or enhance EPPIN-semenogelin binding, and inhibit forward motility of sperm. The assays described herein identify compounds which inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant EPPIN and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies.
Small molecules for inhibiting male fertility
Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. In one embodiment, the compounds described herein mimic the binding of anti-EPPIN antibodies to EPPIN, and thus inhibit the forward motility of sperm in humans and other primates. In another embodiment, the compounds described herein inhibit or enhance EPPIN-semenogelin binding, and inhibit forward motility of sperm. The assays described herein identify compounds which inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant EPPIN and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies.
Macromolecular Antioxidants Based On Dual Type Moiety Per Molecule: Structures, Methods Of Making And Using The Same
Disclosed are compounds represented by structural formula
##STR00001## methods of producing compounds represented by structural formula, and their use in inhibiting oxidation in an oxidizable material.
Macromolecular Antioxidants Based On Dual Type Moiety Per Molecule: Structures, Methods Of Making And Using The Same
Disclosed are compounds represented by structural formula
##STR00001## methods of producing compounds represented by structural formula, and their use in inhibiting oxidation in an oxidizable material.
Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby
A process for preparing a triazine-based precursor for producing a micro-particulate complex containing a far infrared-emissive silica particle comprises steps of: a) subjecting 2-4-6-trichloro-1,3,5-triazine and a first nucleophilic compound to a displacement reaction in the presence of a first solvent at a first temperature range to form an intermediate; and b) subjecting the intermediate and a second nucleophilic compound to a further displacement reaction in the presence of a second solvent at a second temperature range higher than the first temperature range.